

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
29 June 2006 (29.06.2006)

PCT

(10) International Publication Number
WO 2006/067401 A1

(51) International Patent Classification:

C07D 211/26 (2006.01) C07D 295/215 (2006.01)
 C07D 401/04 (2006.01) A61K 31/497 (2006.01)
 C07D 295/20 (2006.01) A61P 29/00 (2006.01)
 C07D 401/06 (2006.01) A61P 35/00 (2006.01)
 C07D 401/08 (2006.01) A61P 31/18 (2006.01)
 C07D 401/12 (2006.01)

4TG (GB). **WATERSON, David** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **WINTER, Jon** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, SE-151 85 Södertälje (SE).

(21) International Application Number:

PCT/GB2005/004895

(22) International Filing Date:

19 December 2005 (19.12.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0428327.1 24 December 2004 (24.12.2004) GB
 0520325.2 6 October 2005 (06.10.2005) GB

(71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London, W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BOWER, Justin, Fairfield** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire, SK10 4TG (GB). **POYSER, Jeffrey, Philip** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire, SK10 4TG (GB). **TURNER, Paul** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire, SK10

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS

(57) Abstract: Compounds of formula (I) Q-L-W-C(=X)-Z-P wherein Q is an amine of the formula -N(R¹)(R²); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y¹ and Y² which are linked to groups L and C(X) respectively and Y¹ and Y² are independently selected from N and C; X is O, N, N-CN or S; Z is NR³; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C-C chemokine mediated conditions.

WO 2006/067401 A1